Advertisement Enlight joins AstraZeneca, Novo Nordisk for therapeutics development - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Enlight joins AstraZeneca, Novo Nordisk for therapeutics development

Enlight Biosciences, an entrepreneurial partnership with pharmaceutical companies, has entered partnerships with AstraZeneca and Novo Nordisk to help the companies in the development of their therapeutic programs.

Enlight emphasizes on areas including molecular imaging, biologics, drug formulation delivery methods, besides novel chemistries, production technologies, biomarkers and drug safety.

Enlight CEO Michelle Browner said the company hopes to benefit from contributions of AstraZeneca and Novo Nordisk.

AstraZeneca Innovative Medicines Executive Vice President Menelas Pangalos said Enlight would provide an opportunity for its biologics arm, MedImmune, to support the development of tools that will improve R&D across the industry.